Professor Eden is an expert on transfer pricing and multinational enterprises (MNEs), with decades of experience consulting to MNEs, governments, and international organizations on transfer pricing and MNE strategies and structures. In transfer pricing matters, she has served as an expert witness – in cases that include Coca-Cola Co. v. Commissioner and In re: Nortel Networks – and filed numerous expert reports. Professor Eden has taught courses on transfer pricing, MNEs, and the economics of international business, and founded the Transfer Pricing Aggies program at Texas A&M University, which has trained hundreds of graduate students. She has extensive research experience in areas such as transfer pricing and MNE strategies in the digital economy, and citations to her publications place her in the top 2% of research scientists worldwide. Professor Eden has authored several books, including Taxing Multinationals: Transfer Pricing and Corporate Income Taxation in North America, Multinationals in North America, The Economics of Transfer Pricing, and Research Methods in International Business. She is a frequent speaker at transfer pricing and tax conferences, as well as a former president and dean of the Fellows of the Academy of International Business. She is a currently a member of the United Nations Tax Committee’s Subcommittee on Transfer Pricing.

Mr. Beach has more than 30 years of experience valuing businesses; rendering fairness opinions; and negotiating, structuring, and closing mergers and acquisitions (M&A), financings, strategic alliances, and joint ventures. During his career, he has closed over 100 M&A transactions and over 100 financings for companies in the technology, health care, consumer products, and financial services industries. He has frequently served as an expert witness in complex litigation matters involving shareholder rights and valuation, and has testified several times in Delaware Chancery Court. As founder and president of Business Consulting Group, LLC, Mr. Beach oversees the firm’s valuation and advisory work for corporate transactions. Earlier in his career, Mr. Beach was head of corporate finance for KPMG and head of investment banking at Advest, Inc. In addition, he was president and co-founder of Boston Corporate Finance, a boutique investment banking firm focused on providing M&A, capital-raising, and general advisory services to global companies in the technology sector. He has served on the board of numerous companies and organizations, and has advised many companies on their strategic development and direction. Mr. Beach has been a guest lecturer at Harvard Business School, Cornell University, and Dartmouth College. He has been a certified public accountant and is a registered principal with the Financial Industry Regulatory Authority (FINRA).

Ms. Cotton has extensive experience conducting complex quantitative and qualitative analyses of data in both mergers and litigation matters. She has supported experts from leading universities and managed case teams in a broad range of industries on matters related to antitrust, bankruptcy, class certification, intellectual property, securities, survey design, tax, and transfer pricing. Her recent case work has included assessing competitive effects in major antitrust matters and mergers; analyzing Federal Trade Commission (FTC), US Department of Justice (DOJ), and Canadian Competition Bureau (CCB) merger compliance, including assistance with Hart-Scott-Rodino (HSR) filings, second requests, divestiture analysis, advocacy, and merger trial testimony; managing the independent evaluation of large-scale transaction and customer datasets in major antitrust matters; examining damages issues in a data breach context; and determining arm’s-length pricing in a large US transfer pricing matter. Ms. Cotton also has substantial experience evaluating questions of commonality and typicality in the context of privacy, technology, data breach, pharmaceutical, medical device, and overcharge class actions.

Mr. Richardson has more than 30 years of experience as a senior executive at institutional asset management firms, most recently as executive director of client service and business development and member of the global management team at Impax Asset Management Group. Throughout his career, Mr. Richardson has been responsible for overseeing the management of institutional investment portfolios of fixed-income, listed equity, and private securities. During the final decade of his tenure as head of Impax’s North American business, these portfolios were managed with a particular focus on the role of environmental, social, and governance (ESG) factors in investment management decisions. He has consulted to public and private companies in numerous industries, including financial services and insurance, on investment, governance, and compliance matters. Mr. Richardson has had oversight of a full range of investment portfolios offered through different fund vehicles, including 40 Act funds, commingled funds, collective trust funds, limited partnerships, and segregated accounts. He has been responsible for client, asset, and revenue growth, as well as new product initiatives and M&A. Mr. Richardson testified at deposition and trial, and has contributed to articles on sustainable investments for media outlets such as the Financial Times, The New York Times, and CNBC. Prior to his work with Impax, he co-founded Global Energy Investors, a private equity infrastructure firm, and Dwight Asset Management, an institutional fixed-income investment firm that was subsequently acquired by Goldman Sachs. He serves as a member of the Global Leadership Council for the World Resources Institute, and as a member of the President’s Council for Ceres. Mr. Richardson is a CFA charterholder.

Dr. Lewis provides economic analysis and expert witness support in a wide range of litigation matters, including antitrust, class certification, and health care cases. His case work has involved cartel allegations in a variety of industries, alleged horizontal and vertical restraints by manufacturers in the technology and construction industries, antitrust claims against brand and generic drug manufacturers, and transfer pricing disputes. Prior to joining Analysis Group, Dr. Lewis was a manager in the economic and statistical consulting group of a financial advisory firm.

Mr. Malinak specializes in financial economics, with particular expertise in damages estimation, applied finance theory, and business and asset valuation. He has provided deposition, arbitration, and trial testimony on economic damages and valuation issues, and has testified on financial integrity, the cost of capital, and economic issues in utility rate hearings and at a Federal Energy Regulatory Commission (FERC) hearing. Mr. Malinak has directed litigation projects in many industries on issues related to securities (including derivative securities), antitrust, breach of contract, taxation, regulatory economics, and intellectual property claims. He has frequently addressed class certification and damages issues in securities fraud cases, as well as the myriad economic, financial, and accounting issues common to most damages calculations, such as cost of capital and prejudgment interest. Mr. Malinak has significant experience in tax-related work, including leading Analysis Group teams in Black & Decker, Inc. v. United States and Chemtech Royalty Associates L.P. v. United States, as well as in financial institutions and risk management, having led consulting teams supporting experts in the Winstar savings and loan litigations. He also completed a major project on the risk of Fannie Mae, resulting in a white paper authored by an academic affiliate. He has served as treasurer, head of the audit and finance committee, and a member of the executive committee and board of directors of the Meridian International Center, an international leadership organization that works with partners in the government, private, NGO, and educational sectors to create lasting international partnerships through leadership programs and cultural exchanges. Prior to joining Analysis Group, Mr. Malinak was a principal at Putnam, Hayes & Bartlett.

Professor Hylton has over 30 years of experience researching legal issues in antitrust, merger, and intellectual property cases. He is an expert on tort law, labor law, civil procedure, and empirical legal analysis. A prolific author, Professor Hylton has published 5 books and more than 100 scholarly articles on topics such as oligopoly pricing, the intersection of antitrust and intellectual property, and damages in patent infringement cases. He is an associate editor of the International Review of Law and Economics, a former contributing editor of the Antitrust Law Journal, coeditor of Competition Policy International, and editor of the Social Science Research Network’s Torts & Products Liability Law eJournal. Professor Hylton is a past president of the American Law and Economics Association, and previously served as the organization’s secretary-treasurer and vice president. He is a member of the American Law Institute and serves on the board of directors of the Pioneer Institute.  Prior to joining Boston University, Professor Hylton was awarded tenure as a faculty member at Northwestern University School of Law and served as a research fellow at the American Bar Foundation.

Dr. Dawson specializes in applying economics and finance to complex problems in business litigation, including intellectual property (IP), false advertising, securities, and finance matters. Her experience spans several industries, from medical devices and high tech to telecommunications and accounting. Dr. Dawson has consulted to counsel in all phases of the litigation process, including understanding complex claims, assisting with fact and expert discovery, and providing trial support. She has served as an expert witness on matters involving false advertising, breach of contract, and copyright infringement. Dr. Dawson’s case work has involved complex data analysis, development of financial models, general damages assessment, evaluation of lost profits, royalty, and other damages remedies in IP and false advertising matters, ascertainment of loss causation and damages in securities fraud matters, and financial statement analyses. She has spoken at various conferences and served as a panelist on the topics of platform economics and IP damages.

Read Na's profile

Dr. Robbins is a pharmaceutical and biotech executive with over 40 years of broad-based industry experience. In his role at Kodiak Strategic Consultants, he consults to a diverse group of pharmaceutical and biotech companies on clinical, regulatory, business development, and licensing issues. Dr. Robbins served as a CEO in residence at the University of Minnesota’s Office for Technology Commercialization and co-founded several biotech ventures. He is actively involved with a number of startups, including GigaMune, Neuropharma Meds, and Diastol Therapeutics. He served as the COO of Bullet Biotechnology, regulatory strategic advisor to GigaGen, and acting CEO of GigaMune, all of which have focused on novel immunotherapies targeting cancer and autoimmune diseases. Dr. Robbins has served as an expert in multiple antitrust matters, intellectual property cases, and contract disputes, and provided testimony at deposition, trial, and arbitration. Prior to his consulting career, he held several senior-level positions at brand and generic pharmaceutical companies, where he was responsible for the development of regulatory and clinical strategies that led to numerous new drug application (NDA), biologics license application (BLA), and abbreviated new drug application (ANDA) approvals by the US Food and Drug Administration (FDA). He has conducted analyses in therapeutic areas that include cardiology, oncology, endocrine/metabolic, women’s health, infectious diseases, radiology, and nuclear medicine and diagnostics. In addition, Dr. Robbins has experience assisting biotech startups with strategy and financing. He holds adjunct professorships in pharmacology at the University of Minnesota Medical School and the University of Minnesota College of Pharmacy, and his work has been published in numerous peer-reviewed scientific journals. Dr. Robbins serves on the Antitrust Council of the Minnesota State Bar Association.

Professor Jena is a health economist, practicing internal medicine physician, and professor of health care policy. His work involves several areas of health economics and policy, including the economics of medical innovation, the economics of physician behavior and the physician workforce, medical malpractice, and the economics of health care productivity. Professor Jena has been retained as an expert in several pharmaceutical and health care industry matters.

A prolific author, Professor Jena is the coauthor of the book Random Acts of Medicine, and he has contributed to more than 150 peer-reviewed articles and articles intended to increase patient understanding, published in outlets including The New England Journal of Medicine and The New York Times. He is a faculty research fellow at the National Bureau of Economic Research and serves on Harvard Medical School’s Standing Committee on Health Policy. Professor Jena is a recipient of the NIH Director’s Early Independence Award to fund research on the physician determinants of health care spending, quality, and patient outcomes, and a recipient of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) New Investigator Award. In 2018, he was listed among 100 great leaders in health care by Becker’s Hospital Review.

Dr. Cliff is a financial economist with expertise in a range of topics, including asset valuation, mergers and acquisitions (M&A), tax shelters, stock analysts’ recommendations, IPOs, REITs, derivatives, and hedge funds. He has extensive experience with large financial datasets, sophisticated econometric models, and simulations. In his consulting engagements, Dr. Cliff has addressed damages modeling, class certification, business and asset valuation, analysis of complex financial structures, analysis of solvency and debt covenants, evaluation of investment strategies, and assessment of due diligence practices. In these assignments, he has managed large case teams, designed and performed analyses in support of expert reports, critiqued opposing expert reports, and assisted with preparation for depositions and trial. Dr. Cliff has also served as an expert on cases involving valuation, damages, and liquidity discounts. Prior to joining Analysis Group, Dr. Cliff was a finance professor for nine years at Purdue University and Virginia Tech, where he taught a variety of courses at the undergraduate, M.B.A., and Ph.D. levels. His academic research has been published in leading journals such as the Journal of Finance, the Journal of Business, and Financial Management.

Professor Blanchard’s research combines experiments with observational data analyses to study how consumers make complex decisions about finance and technology. He serves as a marketing and research expert in commercial litigation and advises financial services and technology companies on business strategies and research. Professor Blanchard is the director of Georgetown’s M.B.A. Certificate in Consumer Analytics and Insights program, and he teaches courses on research design, surveys, and quantitative analyses to undergraduate, graduate, and executive education program students. He has been named among the best 40 business professors under 40 by Poets&Quants, and a Young Scholar by the Marketing Science Institute. 

Professor Blanchard is an associate editor of the Journal of Marketing Research, the Journal of Consumer Research, and the International Journal of Research in Marketing, and he has published articles in a number of prominent marketing journals. Professor Blanchard’s research and perspectives on consumer finances and technology have been featured in media outlets such as Forbes, Fortune, Harvard Business Review, NerdWallet, The New York Times, Marketplace, and NBC News. In addition to serving on the Georgetown faculty, he served as a member of the American Marketing Association’s Academic Council, and held visiting positions at Dartmouth College and Columbia University.  

Mr. McLean specializes in applying finance and economics to problems in complex business litigation, including securities, valuation, tax, and intellectual property (IP) matters. His experience spans several industries, from banking, insurance, and high tech to telecommunications and health care. He has served as an expert witness, and has provided assistance in many phases of litigation, including development, presentation, and review of pretrial discovery; preparation of testimony; and critique of analyses of opposing experts.

Mr. McLean’s case work has included general damages analyses, lost profit and reasonable royalty calculations related to IP misappropriation, and assessments of fiduciary duties and investment management. In addition, he has evaluated the economic characteristics and risk transfer of a range of financial instruments, such as private mortgage insurance, subprime loans, and preferred equity in a new venture. He has led large case teams in a number of high-profile matters, including consulting to the US Department of Justice (DOJ) regarding the financial issues involved in tribal trust fund disputes, and supporting counsel for a large electronics manufacturer in litigation associated with features on smartphones and tablets.

In addition, Mr. McLean has presented on topics related to damages assessment and patents. He has also worked with entrepreneurial companies, helping to develop financial projections, business plans, and marketing strategies.

Mr. Jenson has extensive experience managing complex high tech capital equipment businesses for public and private equity companies. He has more than 30 years of experience in global manufacturing focusing on general management, marketing, sales, and product development. His experience includes automation systems, robotics, thin-film process equipment, material handling equipment, industrial equipment, and analytical instrumentation. Mr. Jenson has participated in numerous mergers and acquisitions (M&As), as part of both the acquiring firm and the acquired firm. His M&A experience includes investment target identification, valuation, due diligence, integration, and management of acquired companies. In his position as general manager of core technologies for Ocean Insight – a spectroscopy and imaging technology company – Mr. Jenson leads the global sales, marketing, and product development teams. Prior to his work with Ocean Insight, he led the $200 million waterjet cutting systems business segment of SHAPE Technologies Group, managed the $250 million compound semiconductor equipment business unit of Veeco Instruments, and served as a senior leader in automation solutions for the semiconductor and flat panel display industries at Brooks Automation. Mr. Jenson is also a veteran submarine officer of the US Navy.

Dr. DerSarkissian’s expertise includes the application of epidemiologic methods to real-world evidence (RWE) generation in support of product registration, post-approval safety studies, and health economics and outcomes research (HEOR). She has served as an expert witness in litigation and has a wide range of experience in pharmacoepidemiology, biostatistics, and observational data analysis, including in studies on causal methods. Dr. DerSarkissian has provided regulatory and strategic consulting on drug and medical device registration and conducted RWE studies related to US Food and Drug Administration (FDA) and European Medicines Agency (EMA) submissions. She has conducted cost-effectiveness and comparative effectiveness studies; examined treatment patterns, drug adherence, health care resource utilization and costs, and clinical outcomes; assessed direct medical and indirect productivity costs of a disease burden; and assessed patient-reported quality of life and the humanistic burden of a disease. Dr. DerSarkissian has used data from electronic medical records, clinical trials, commercial insurance claims, patient surveys, and medical chart review studies in disease areas that include obesity; HIV/AIDS; cardiovascular diseases; schizophrenia; autoimmune, neurologic, and rare hereditary disorders; and many types of cancer. She has presented her research at conferences on epidemiology and health services, and published articles in a number of peer-reviewed journals. Dr. DerSarkissian is an adjunct assistant professor in the epidemiology department at the UCLA Fielding School of Public Health.

Read Maral's profile

Professor Rock is an expert in corporate law and corporate governance. He coauthored the book The Anatomy of Corporate Law: A Comparative and Functional Approach, and has published numerous articles on topics such as poison pills, politics and corporate law, hedge funds, corporate voting, proxy access, corporate federalism, and mergers and acquisitions. Prior to joining the NYU faculty, Professor Rock taught at the University of Pennsylvania Law School, where at various times he served as co-director of the Institute for Law and Economics, associate dean, senior advisor to the president, and provost and director of open course initiatives. He has held visiting professorships at NYU and Columbia University, and was a Fulbright Senior Scholar at Hebrew University. Prior to his academic career, Professor Rock worked as an attorney specializing in complex antitrust, corporate, and securities litigation. In January 2019, the American Law Institute named him Reporter for the Restatement of the Law, Corporate Governance.

Professor Knittel’s research focuses on industrial organization, applied econometrics, and energy and environmental economics. He has provided trial and deposition testimony in a number of litigation matters, including valuing product features in smartphones, PCs, and contact lenses. He has also consulted to Delta Airlines, Ford Motor Company, the US Energy Information Administration, and Korea Electric Power Company. Professor Knittel has authored or coauthored numerous articles on topics such as market structure and product pricing, tacit collusion, and challenges in merger simulation analysis. Examples of his research include articles on the spurious correlation between ethanol production and gasoline prices, unilateral market power in the electricity reserves market, and tacit collusion in credit card markets. His research has appeared in the American Economic Review, the American Economic Journal: Macroeconomics, the American Economic Journal: Economic Policy, The Review of Economics and Statistics, The Journal of Industrial Economics, and The Energy Journal, among other academic publications. He is a former coeditor of the Journal of Public Economics and serves or has served as an associate editor for several other scholarly journals, including the American Economic Journal: Economic Policy, The Journal of Industrial Economics, the Journal of Transport Economics and Policy, and The Journal of Energy Markets. Professor Knittel is a research associate at the National Bureau of Economic Research (NBER) in the Productivity, Innovation, and Entrepreneurship and Industrial Organization programs, and he co-directs the Environment and Energy Economics program.

Mr. Cohen has over 30 years’ experience as an expert in international arbitration, valuation, antitrust, intellectual property, and securities, and has testified in arbitration and federal courts on many aspects of economic damages. He specializes in fields that are intensive in intangible assets such as patents, copyrights, trademarks, and trade secrets. He has worked across a wide range of industries, including health care, software and technology, financial services, energy, transportation, and entertainment.

Mr. Cohen has worked with significant corporations including Apple, Microsoft, Oracle, Wells Fargo, State Street, Wachovia, SoundExchange, ASCAP, Liberty Mutual, Allstate Insurance, Johnson & Johnson, AstraZeneca, Astellas, United Airlines, TWA, DaimlerChrysler, Mitsubishi, and Anheuser-Busch. He also has experience in matters related to the US Federal Trade Commission, the US International Trade Commission, the Tax and Antitrust Divisions of the US Department of Justice, the Republic of Uruguay, and the Commonwealth of Australia.

Mr. Cohen is the author of Intangible Assets: Valuation and Economic Benefit and a contributor to the American Bar Association publication Proving Antitrust Damages. He has been a guest lecturer at both Northwestern University and The University of Chicago. He is also a prolific songwriter.

Ms. Glowka is a chartered accountant who specializes in the assessment of damages and forensic analysis arising in the context of dispute resolution. She has served as an expert and led consulting teams on complex UK and international assignments, including litigation and international arbitration matters in all the major international arbitration forums, as well as before the High Court of Justice in London, the Scottish Court of Session, and the UK Competition Appeal Tribunal.

Ms. Glowka has acted on a broad range of litigation and arbitration matters across the automotive, oil and gas, pharmaceutical, telecommunications, software, and consumer products industries, among others. Her litigation and arbitration work has involved the evaluation of damages arising in the context of contractual and shareholder disputes, as well as post-transaction disputes such as breach of warranty claims. Ms. Glowka’s forensic accounting work has spanned the analysis and tracing of funds and transactions, as well as the evaluation of fraud and accounting irregularities, including allegations of accounts manipulation for inflating performance-related bonuses and purchase consideration. She has also evaluated complex financial reporting issues under a variety of accounting standard-setting regimes, including UK generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRS). Ms. Glowka is a member of Chartered Accountants Australia and New Zealand.

Mr. Bodington specializes in the business and finance aspects of the electric power industry. He is the founder of a boutique investment banking firm that has provided M&A, financing, and restructuring advisory services to the energy sector for more than 25 years. Mr. Bodington has played a key role in more than 100 transactions with an aggregate value of more than $7 billion. In these engagements, he has led the purchase and sale of interests in power projects; arranged debt and equity financing for energy projects in development, construction, and operation; and advised owners and lenders on various capitalization, value, repayment, restructuring, and management issues. His clients include industrial companies, independent power companies, equity investors, lenders, utility affiliates, and regulated utilities. 

Mr. Bodington is also a seasoned expert witness who has provided testimony for clients on finance and damages issues. Prior to founding Bodington & Company, he spent eight years with Bechtel Group and four years with an international management consulting firm. Mr. Bodington is the author of more than 50 articles on a variety of economic and financial topics relevant to the energy sector. He holds Financial Industry Regulatory Authority (FINRA) Series 7, 24, 63, 79, and 99 licenses.

Pierre Cremieux, President of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the US and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings.

Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor-related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years.

His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals including the George Mason Law Review, the American Bar Association Economics Committee Newsletter, The Review of Economics and Statistics, the Journal of Health Economics, Industrial and Labor Relations Review, the Journal of Clinical Oncology, and the American Journal of Managed Care. Dr. Cremieux's research has been cited in leading media outlets including The Wall Street Journal and Forbes.

Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and Yale's School of Management.

Prior to joining Analysis Group in 1997, Dr. Cremieux spent five years as a professor at the University du Québec à Montréal, and served as an adjunct professor from 1997 to 2018.

A former chief economist at the Federal Communications Commission (FCC), Professor Rogerson focuses his research on applied microeconomic theory, industrial organization, regulation, cost accounting, telecommunications, and defense procurement. He has been an active participant in media transactions before the FCC, including Comcast/NBCUniversal and News Corp./DirecTV, as well as various rulemaking proceedings. Professor Rogerson was also the FCC’s senior economist, supervising its economic analyses of the Comcast/Time Warner Cable, AT&T/DirecTV, and Charter Communications/Time Warner Cable transactions. He has also served as an economic expert for the US Department of Justice, Federal Trade Commission, and the National Association of Attorneys General in various antitrust cases in the telecommunications, media, and defense industries. Professor Rogerson has published a number of articles and book chapters on topics such as vertical mergers in the video programming and distribution industry, and incentives for investment and innovation as related to the regulation of broadband telecommunications. He is a former editor of Economic Inquiry and Defense and Peace Economics, and a former member of the editorial boards of both the Review of Accounting Studies and The Journal of Industrial Economics. He served two terms as chair of Northwestern University’s Department of Economics, and currently holds several leadership roles at Northwestern, including research director of the Program on Antitrust Economics and Competition Policy at the Searle Center on Law, Regulation, and Economic Growth; director of the Center for Business Institutions; and co-director of the Center for the Study of Industrial Organization.

Dr. Duh, Chief Epidemiologist at Analysis Group, specializes in real-world evidence (RWE) generation for product registration, post-approval safety studies, and health economics and outcomes research (HEOR) of pharmaceuticals, vaccines, and regenerative biotherapeutics. She has led multiple projects for new molecular entity approvals and product label expansion applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as health technology assessment (HTA) research for submissions to national payers such as the Centers for Medicare and Medicaid Services (CMS) in the US and the UK’s National Institute for Health and Care Excellence (NICE). Her extensive research has appeared in over 315 peer-reviewed publications.

Her work also extends to pharmaceutical liability litigation and securities fraud litigation related to adverse drug events that allegedly led to product recalls, market withdrawals, black box warnings, and FDA limited access programs.

Dr. Duh is also an adjunct in the biostatistics department at the Harvard T.H. Chan School of Public Health. She served as a chairperson of drug safety and epidemiology for the Drug Information Association (DIA) and was an adjunct assistant professor of pharmacoeconomics and pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health’s (FNIH’s) Observational Medical Outcomes Partnership (OMOP). She has served as a peer reviewer for several journals, including PharmacoEconomics, the American Journal of Health-System Pharmacy, Chest, Pharmacoepidemiology and Drug Safety, the American Journal of Kidney Diseases, and Therapeutics and Clinical Risk Management. Dr. Duh is also an elected member of the American Society of Hematology and a member of the American Society of Clinical Oncology, the International Society of Pharmacoepidemiology, and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

View Dr. Duh's selected publications on the Harvard Catalyst website

Professor Levinsohn is an expert in antitrust, industrial organization, and econometrics. He has provided expert reports and testimony in several landmark antitrust and regulatory matters, including In re: TFT-LCD (Flat Panel) Antitrust Litigation, In re: Vitamins Antitrust Litigation, In re: New Motor Vehicles Canadian Export Antitrust Litigation, and the Tobacco Master Settlement Agreement proceedings. He has also consulted to numerous foreign governments and international organizations.

Professor Levinsohn conducts research in industrial organization, applied econometrics, international economics, and development economics. He has served on the editorial boards of American Economic Review, The Review of Economics and Statistics, the Journal of International Economics, and the Journal of Economic Literature. Prior to joining the Yale faculty, Professor Levinsohn was the J. Ira and Nicki Harris Family Professor of Public Policy at the Gerald R. Ford School of Public Policy at the University of Michigan.

An accomplished practicing physician, Dr. Jha is a global expert on public health and health policy. A leader in the area of pandemic preparedness and response, he was appointed White House COVID-19 Response Coordinator by the Biden administration. In this role, he led work to increase the development of and access to treatments and vaccines, improve testing and surveillance, facilitate major investments in indoor air quality measures, and put in place an infrastructure to respond more effectively to disease outbreaks. Dr. Jha’s research focuses on improving the quality and cost of health care delivery, using global health policies to address the challenges of the COVID-19 pandemic, and crafting better policy to improve health outcomes in the US and worldwide. He has published hundreds of research publications in peer-reviewed journals and has consistently been ranked in the top 1% of most cited researchers. Prior to joining the Brown School of Public Health, Dr. Jha was a professor at the Harvard T.H. Chan School of Public Health and Harvard Medical School. He also served as the faculty director of the Harvard Global Health Institute and held various leadership roles at the Harvard T.H. Chan School of Public Health. Dr. Jha currently serves as a member of the BMJ international advisory board and has been a member of the National Academies of Sciences, Engineering, and Medicine since 2013.

Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has extensive experience with issues involving competition, intellectual property, marketing, pricing, and valuation with a focus on the health care industry. He has evaluated questions of class certification, damages, liability, and market definition in antitrust matters. He also has provided economic analyses and expert testimony on causation, damages, and valuation in a variety of health care cases, including cases involving allegations of False Claims Act (FCA), Anti-Kickback Statute (AKS), and Lanham Act violations. In addition to his work in litigation, Dr. Mortimer has assisted pharmaceutical and medical device manufacturers on pricing and contracting issues and authored several public policy studies related to legislation establishing a biosimilar approval pathway, biosimilar competition, pharmaceutical pricing, generic drug competition and the role of authorized generic entry, and paragraph IV abbreviated new drug application (ANDA) filings. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.

Professor Haas-Wilson is an expert in health care antitrust, including the competitive effects of hospital mergers and commercial health insurer mergers, the effects of vertical consolidation in health care markets, and the implications of physician networks on competition in the health care industry. She recently testified in Federal District Court in Idaho on behalf of plaintiffs, in an antitrust lawsuit alleging competitive harm from St. Luke’s Health System’s acquisition of a large independent physician practice. She has served as a consultant on antitrust issues to the Federal Trade Commission, the Massachusetts Attorney General, the California Department of Corporations, and numerous private entities. She also testified on behalf of the Federal Trade Commission in the matter of Evanston Northwestern Healthcare Corporation. Professor Haas-Wilson is the author of Managed Care and Monopoly Power: The Antitrust Challenge and coeditor of Uncertain Times: Kenneth Arrow and the Changing Economics of Health Care. Her research has appeared in the Journal of Political Economy, the Journal of Economic Perspectives, the Journal of Law and Economics, the Review of Economics and Statistics, and the Journal of Health Economics, among others.

Professor Pindyck is a leading industrial organization economist and testifying witness in the areas of antitrust and intellectual property. His research and writing have covered topics in microeconomics and industrial organization, the behavior of resource and commodity markets, financial markets, and econometric modeling and forecasting. His recent work in economics and finance has examined the determinants of market structure and market power, the dynamics of commodity spot and futures markets, criteria for investing in risky projects, the role of R&D, and the value of patents. He has received many academic honors, including several awards for outstanding teaching, and holds senior editorial positions with a number of publications. Professor Pindyck has consulted to dozens of public and private organizations, including the Federal Trade Commission, IBM, and AT&T, and has been deposed and/or testified in over a dozen cases in diverse industries such as food, energy, software, medical devices, and airlines. He has worked with Analysis Group on many of these cases, including the Lotus v. Borland litigation, in which Professor Pindyck used econometric modeling techniques to identify the economic value of various attributes and isolated the value of the infringing features. He also worked with Analysis Group in a major litigation matter involving price-fixing allegations, in which he examined allegations of accumulation of buying power and the resulting effects on negotiations with suppliers.

Professor Happe is a licensed pharmacist with more than 20 years of experience as an academic and a senior executive across health care consulting, pharmaceutical research, managed care, and graduate education. Her areas of expertise include pharmacy benefit management, drug coverage policy, pricing and payment flows throughout the supply chain, pharmacoeconomics, health outcomes research, and epidemiology. Prior to joining the University of Florida, Professor Happe was the chief pharmacy officer at Humana Pharmacy Solutions, where she directed the outcomes research and policy teams and led the enterprise opioid task force. She also served as Humana’s director of research and publications, contributing to more than 70 articles published in peer-reviewed journals. Professor Happe is editor in chief of the Journal of Managed Care & Specialty Pharmacy.

Professor Bucklin is an award-winning research specialist in the quantitative analysis of customer purchase behavior. He is an expert on applied choice models in marketing, channels of distribution, and pricing policies. Professor Bucklin has testified or been deposed in numerous cases involving antitrust and damages issues and most recently served as an expert in the Google AdWords litigation. In his current consulting work, Professor Bucklin focuses on quantitative tools to improve corporate marketing decision making and analysis of the variables involved in consumer choice. He has published extensively on topics related to website browsing, e-commerce purchase behavior, and marketing models. His articles have appeared in the Journal of Marketing Research, Marketing Science, the Journal of Retailing, and Marketing Letters: A Journal of Research in Marketing. He also serves on the editorial board of Marketing Letters. Professor Bucklin previously worked as a consultant at Bain & Company and as a business journalist for The Washington Post.

Professor Keller is an expert on marketing management, branding, and brand equity. His research focuses on improving marketing strategies through an understanding of consumer behavior, as well as on the design, implementation, and evaluation of integrated marketing communication programs. Professor Keller has served as brand advisor to a number of large corporations, including Accenture, American Express, Disney, Ford, Intel, Levi-Strauss, L.L. Bean, Nike, Procter & Gamble, and Samsung. He has published over 120 papers in peer-reviewed journals such as the Journal of Marketing, the Journal of Marketing Research, and the Journal of Consumer Research. He also authored the widely used textbooks Marketing Management (with Philip Kotler) and Strategic Brand Management. Professor Keller has received numerous awards for his research accomplishments, and has conducted marketing seminars for executives in a variety of forums. He previously held faculty positions at the University of California, Berkeley; Stanford University; and the University of North Carolina at Chapel Hill.

Ms. Filsoof has conducted economic and financial analyses and managed case teams in support of academic and industry experts in a broad range of finance and securities, antitrust, and commercial litigation matters. Her finance and securities case work has included examining allegations of securities fraud, evaluating investment compliance and suitability and compliance with fiduciary duties, assessing corporate governance, analyzing investment management fees, analyzing the performance of mortgages and mortgage-backed securities (MBS), and assessing the appropriateness of class certification. Ms. Filsoof has supported industry and academic experts on a variety of topics related to MBS, including due diligence, loan underwriting, appraisal, trustee duties, and damages. She has also supported industry experts in addressing regulatory compliance and banking practices, including issues related to fraud, Bank Secrecy Act (BSA) and Anti-Money Laundering (AML) compliance, third-party lending relationships, and mortgage lending. Ms. Filsoof’s antitrust case work has included analyzing market structure and competitive dynamics, evaluating the competitive effects of mergers, assessing the appropriateness of class certification, and estimating antitrust damages. Her case work has spanned multiple industries, including financial services, insurance, payment cards, high tech, aviation, and pharmaceuticals. She has substantial experience in payments and has supported academic and industry experts in multiple litigation and consulting engagements involving payment cards and emerging payment methods. Ms. Filsoof has provided assistance to attorneys in all phases of the litigation process, including case strategy, discovery, expert reports, deposition, and trial.

Professor Rossiter is an expert in health economics who has testified or served as an expert in the following areas: competition in the financing and delivery of health services; reimbursement economics, especially for Medicare, Medicare Advantage, and Medicaid; managed care organizations; prescription medicines; survey research; and health information analytics. Professor Rossiter is the former secretary of health and human resources for the Commonwealth of Virginia. In that role, he was responsible for over 15,000 employees in 13 agencies (including 10 state mental hospitals), brought major information technology projects in the Secretariat to national prominence, and made major reforms in Virginia Medicaid. He also served as deputy for policy to the Administrator of the Centers for Medicare and Medicaid Services (CMS). As deputy, he created and directed a new payment system for US hospitals under Medicare, was responsible for the CMS strategic plan, and formulated all agency policy initiatives through the federal legislative process.

Prior to joining the William & Mary faculty, Professor Rossiter was a professor of health administration at Virginia Commonwealth University. He served on the board of regents of the National Library of Medicine, National Institutes of Health; on the board of directors of AcademyHealth; and as chair of the board of directors of the Coalition for Health Services Research, the lobbying arm of AcademyHealth, during the passage of the Affordable Care Act. He has also served on numerous advisory groups, including the National Advisory Council for Healthcare Research and Quality, and is currently a trustee and chair of the Williamsburg Health Foundation. Professor Rossiter is the author or editor of 15 books, and the author of over 50 journal articles on health economics and the role of competition in the financing and delivery of health services.

Professor Reibstein’s research focuses on competitive marketing strategies, metrics, and product line decisions, among other topics. He has provided marketing management education and consulting research to companies in the consumer goods, pharmaceutical, and oil and gas industries, among others. His consulting activities have included numerous applications of conjoint analysis and other survey techniques in engagements spanning a wide range of products. Professor Reibstein has submitted expert reports and provided testimony on marketing and marketing research in several litigation matters, including analyses of smartphone features in a patent dispute, health claims in a false advertising dispute, and pharmaceutical detailing in a co-marketing dispute.

His recent work includes assessing strategies to address competitors’ reactions to marketing actions and developing metrics that link marketing decisions to financial consequences, which was published in his book, Marketing Metrics: The Definitive Guide to Measuring Marketing Performance. Professor Reibstein is also the author or coauthor of numerous books and chapters in books on subjects including competitive marketing strategy, global branding, and marketing performance measurement. Professor Reibstein has also written several papers on conjoint analysis and its validity and reliability. His research has been published in leading academic journals, including Marketing Science, the Journal of Marketing Research, and the International Journal of Research in Marketing.  

Professor Reibstein has been honored with more than 30 teaching and publishing awards, including the John S. Day Distinguished Alumni Academic Service Award from Purdue University’s Krannert School of Management. He has served as the chairman of the American Marketing Association board of directors and as the executive director of the Marketing Science Institute.

Mr. Darling consults to clients and provides expert testimony to address litigation, strategy, regulatory, and policy questions in a wide range of antitrust and competition, class certification, health care, energy, and environmental matters. He has submitted and supported expert testimony before US district and appellate courts, state utility commissions, siting boards, and federal agencies. He has also assisted clients with responses to government investigations and presented findings before US Attorneys’ Offices, state attorneys general, and the US Drug Enforcement Administration.

In the areas of health care and antitrust, Mr. Darling has extensive experience supporting clients on issues related to discovery and data production, class certification, patent infringement, market definition and market power, and competitive effects in pharmaceutical and life sciences matters involving patent infringement issues, reverse payment settlements, and product hop allegations. He has also designed and implemented customized suspicious order monitoring (SOM) and loss prevention programs for controlled substances, and has experience in False Claims Act and Anti-Kickback Statute litigation cases, including analyses of causation and damages calculations.

Mr. Darling is also an expert on electricity, oil, and natural gas pricing, markets, and infrastructure. His consulting work on behalf of utilities, state and regional organizations, and global companies includes projects related to cost/benefit analyses of new plant construction and retirements; ratepayer and bill impacts; environmental effects of emissions and pollution controls; economic impacts of energy projects, mergers, and policies; natural gas, biomass, and other market studies; and climate change matters including decarbonization policy proposals and quantification of the impacts of greenhouse gas emissions. He has conducted and overseen numerous economic and bill impact assessments in support of projects and policy proposals, ranging from new power plants and transportation facilities to electric, petroleum, and natural gas transmission infrastructure.

Ms. Hitscherich specializes in corporate acquisitions, leveraged buyouts, exclusive sales and divestitures, takeover defenses, and restructurings. She has served as an expert witness in several complex securities litigations, including matters involving deal structure, valuation, due diligence, custom and usage in the finance industry, and financing alternatives.

Ms. Hitscherich has extensive experience in investment banking and corporate law practice, including as a managing director in mergers and acquisitions with Banc of America Securities, where she was secretary of the Fairness Opinion Review Committee; vice president in mergers and acquisitions with J.P. Morgan & Co., where she was a founding member of the takeover defense team and a senior member of the acquisitions fairness Advisory Review Committee; and as a mergers and acquisitions attorney with Skadden, Arps, Slate, Meagher & Flom.

Dr. Cain is an expert in securities litigation, corporate disclosures, M&A litigation, private equity, valuation, insider trading, and corporate governance. He has provided economic analysis, consulting, and expert witness testimony on a variety of finance topics for investigations, settlement negotiations, and trials. He has estimated event studies and trading profits in relation to allegations of insider trading, improper trading behavior, corporate misrepresentations and disclosures, and unregistered stock sales on behalf of the US Securities and Exchange Commission (SEC), US Department of Justice (DOJ), Commodity Futures Trading Commission (CFTC), and other clients. Dr. Cain worked for several years at the SEC, where he was an advisor to Commissioner Jackson and a financial economist in the Office of Litigation Economics. Prior to joining the SEC, Dr. Cain was an assistant professor of finance at the University of Notre Dame Mendoza College of Business. He has published research in numerous journals on topics that include investment banking and fairness opinion valuations, merger contracts and terminations, corporate governance and shareholder activism, hostile takeovers, earnout clauses, merger-related litigation, and management buyouts. Dr. Cain’s research has been cited in forums such as the US Chamber Institute for Legal Reform, amicus briefs to the US Supreme Court, trial verdicts of the Supreme Court of the State of New York and the Delaware Chancery Court, and The International Comparative Legal Guide to Mergers and Acquisitions. His research has also been highlighted in media outlets such as The Wall Street Journal, The New York Times, the Financial Times, and Forbes.

Dr. Rice is an economist with a range of expertise in health economics, industrial organization, finance, statistics, and econometrics. He has extensive experience applying economic theory and statistical methods in complex litigation and research settings. Dr. Rice has led analyses related to government investigations and litigation matters, where he has supported counsel and served as an expert on alleged False Claims Act (FCA) violations, as well as on antitrust, cryptocurrency, insider trading, misappropriation of trade secrets, and breach of contract issues. In matters related to liability and damages, he conducts empirical analyses involving large-scale databases on a range of topics, including causal inference, merger simulation, and lost profits and budget impact. Dr. Rice’s case experience has involved assisting in the preparation of expert reports, testimony, and rebuttal analyses and arguments; developing sophisticated interactive models enabling real-time damages assessments under alternative scenarios; and presenting analyses to US Attorney’s Office investigators. In addition to his litigation work, he has provided econometric and statistical consulting on matters such as risk management, fair market valuation, and compliance. Dr. Rice is an adjunct faculty member of the Harvard University Department of Economics and has taught undergraduate courses on econometrics, health economics, industrial organization, and regulatory economics. He has published extensively in numerous peer-reviewed journals, and presented at conferences and seminars.

Professor Kinch is a drug development expert specializing in cancer, immunological, and infectious diseases. His research focuses on combining cutting-edge science and entrepreneurship to improve public health. During his tenure at Washington University in St. Louis, Professor Kinch founded the Center for Research Innovation in Biotechnology (CRIB). At Long Island University (LIU), he directed CRIB, which uses tools such as the Clinical Drug Experience Knowledgebase (CDEK) to assess trends in drug discovery and development. Professor Kinch also co-founded the Center for Drug Discovery (CDD) to identify and underwrite the university’s most promising drug discovery projects. He has been issued more than a dozen US patents, published more than 100 patent applications, and written several books and book chapters on the commercialization of biopharmaceutical innovation, as well as other aspects of drug development. Professor Kinch has published widely in peer-reviewed journals, including Drug Discovery Today, Science, Cell Chemical Biology, and Biotechnology Law Report, and his research has been profiled in media outlets such as The Wall Street Journal, NPR, CBS News, and The New York Times. Prior to his positions at LIU and Washington University, he was the managing director of the Yale Center for Molecular Discovery. Professor Kinch has also taught at Johns Hopkins University and Purdue University, and held senior scientific research positions at Functional Genetics and MedImmune. He has served on the board of the American Cancer Society and on scientific advisory boards for several biopharmaceutical companies.

Dr. Garces is an economist with deep public- and private-sector antitrust policy and regulation experience in the US and Europe, including serving in the European Commission’s Directorate-General for Competition (DG COMP) and Directorate-General for Internal Market and Industry. Her consulting and case work experience includes mergers and conduct cases in the telecommunications, media, industrial, consumer staples, and technology sectors. She has corporate experience at a large technology company and is widely recognized as an expert on the economic analysis of new digital business models, as well as on regulation in innovative sectors. Dr. Garces has published extensively on topics such as the antitrust analysis of commercial practices, the assessment of conglomerate mergers, the interaction between antitrust and privacy, value creation processes in platform businesses, and behavioral economics. She is also a coauthor of the widely used book Quantitative Techniques for Competition and Antitrust Analysis.

Professor Riddiough is best known for his work on real options, mortgage pricing and strategy, REITs, and land use regulation. He has served as an expert in numerous real estate-related matters, in which he has testified on appraisal and the value of distressed mortgages. Professor Riddiough has consulted to numerous organizations, including the US Department of Housing and Urban Development, GMAC, Wells Fargo, Coldwell Banker Commercial, The Equitable Life Assurance Society, and the State of Wisconsin Investment Board. He has published more than 40 scholarly articles. He has served on the boards of directors of several organizations, including ArCap REIT, EquiBase Capital Partners, and the American Real Estate and Urban Economics Association. Professor Riddiough is the recipient of best dissertation and best paper awards in real estate economics, and is a fellow at the Real Estate Research Institute and a past fellow at the Homer Hoyt Institute. He teaches courses in real estate finance, real estate capital markets, and microeconomics.

Professor Hochberg specializes in entrepreneurship, innovation, venture capital, and private equity, focusing on venture capital networks, entrepreneurial finance, seed accelerators, and corporate governance and compensation. Her research covers topics such as venture capital investment performance, the effects of networks and syndication on venture capital firms, and investment selection. Professor Hochberg has also explored the private equity investment choices of pension funds and other institutional investors, as well as broad-based option compensation in firms. She is the managing director of the Seed Accelerator Rankings Project, which publishes annual rankings of accelerator programs in the US. Prior to joining the Rice faculty, she held positions at the Kellogg School of Management at Northwestern University and the Samuel Curtis Johnson Graduate School of Management at Cornell University. She has taught courses on entrepreneurial finance and health care innovation, and has served as an associate editor of several finance journals, including the Journal of Empirical Finance and the Journal of Banking and Finance. Professor Hochberg is a recipient of the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship, and a research associate at the National Bureau of Economic Research. Prior to joining academia, she was a software engineer at both established and startup technology companies, and co-founded a startup. Professor Hochberg is an active angel investor and advisor to startups, and a Landmark Fellow with Landmark Partners, a large private equity investor in secondary markets. She is a co-founder of Flywheel Innovation, a corporate innovation advisory firm.

Mr. Davis specializes in applying financial economics and data analysis to major litigation matters, with a focus on agricultural markets and pharmaceutical products. He has experience managing case teams, supporting academic affiliates and industry experts, and assisting clients through all phases of complex business litigation, including fact discovery, class certification, merits, trial, and settlement. Mr. Davis’s agricultural experience includes antitrust matters involving allegations of market power in animal protein markets, matters involving the presence of genetically modified products in US grain supplies, and matters involving international trade in agricultural products. His pharmaceutical work includes antitrust matters involving allegations of delayed generic entry, False Claims Act matters involving allegations related to the promotion of pharmaceuticals, and disputes pertaining to the commercial reasonableness of firm conduct.

Mr. Davis also has experience conducting economic research across a variety of industries, including financial services, agriculture, and pharmaceuticals, and analyzing issues related to commodity markets, futures prices, intellectual property and patents, industrial organization and antitrust law, and financial market infrastructure. He is a CFA charterholder. 

Professor Carlson specializes in the marketing management implications of consumer decision-making processes, including the development of brand preferences and the influence of emerging preferences on the decision making process. Though much of Professor Carlson's research explores consumer decision making, he also studies how voters, jurors, and managers make decisions. Over the last 20 years, he has run thousands of surveys, sampling U.S. and international populations.

Professor Carlson has served as an expert in evaluating a survey in a class action matter, consulted on a high profile class action settlement involving consumer deception, and testified before the SEC in an equity trust matter. Professor Carlson's published research can be found in top marketing, psychology, and management journals. He is also the coauthor of Contemporary Brand Management. He blogs for Psychology Today and Forbes, and maintains an active Twitter account (@ProfKurt). While teaching at Georgetown University between 2009 and 2017, Professor Carlson was director of the Georgetown Institute for Consumer Research and co-director of the McDonough School of Business Behavioral Research Lab, and he received the MSB Dean's Distinguished Faculty Research Award and the Decision Analysis Society's Publication Award.

Professor Klausner teaches courses on corporate law, corporate governance, business transactions, and regulation of financial institutions. In recent years, most of his writing has been on corporate governance. He maintains a database on securities class actions and SEC enforcement actions, and has written papers and blog posts based on that database. In addition, Professor Klausner is currently writing a book and producing an online course called Deals: The Economic Foundations of Business Transactions.

Before beginning his academic career, Professor Klausner practiced law in Washington, DC, and Hong Kong. He was a White House fellow from 1989 to 1990, a law clerk for Judge David Bazelon on the United States Court of Appeals for the District of Columbia Circuit in 1981-82, and a law clerk for Justice William Brennan on the United States Supreme Court.

Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes (PROs), safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.

Professor Savitz focuses his epidemiological research on a wide range of public health issues, from the health effects of environmental agents in the workplace and community to a wide range of reproductive health outcomes. He has served as principal investigator on more than three dozen public health studies, including as one of three epidemiologists to evaluate the probable causal link between exposure to perfluorooctanoic acid and the development of certain diseases. Professor Savitz submitted an expert report on behalf of the plaintiffs at the class certification stage of a litigation matter and has consulted on a wide range of issues related to both environmental and reproductive epidemiology. He is the author of more than 300 journal articles and has edited or authored three books, including Interpreting Epidemiologic Evidence: Connecting Research to Applications. Professor Savitz has served as the editor of Epidemiology and the American Journal of Epidemiology, a member of the Epidemiology and Disease Control Study Section of the National Institutes of Health, president of the Society for Epidemiologic Research and the Society for Pediatric and Perinatal Epidemiologic Research, and North American regional councilor for the International Epidemiological Association. He is a member of the National Academy of Medicine and served as vice president for research at Brown University.

Dr. Rothman specializes in the economic analysis of antitrust and competition issues. He has supported economic experts on multiple merger matters on behalf of the US Department of Justice (DOJ), the US Federal Trade Commission (FTC), and merging parties. He has also been retained by multiple private parties to present analyses to the DOJ and FTC and has testified for the DOJ and FTC as an expert witness in merger litigation. In addition to his merger work, Dr. Rothman has worked on multiple joint conduct and unilateral conduct matters.

Dr. Rothman is a senior editor of the Antitrust Law Journal. He has published research in outlets including Antitrust Law Journal, The Antitrust Source, Journal of Health Economics, Journal of Competition Law & Economics, and Concurrences: Competition Law Journal. Dr. Rothman has taught a course on the economics of merger analysis in the economics department at Harvard University. Prior to joining Analysis Group, he was an assistant professor at Columbia University.

Professor Schoar is an expert in corporate finance, entrepreneurship, and organizational economics. Her research examines returns and capital flows in the venture capital industry, the financing of small- and medium-sized enterprises and startup firms in emerging markets, and the impact of corporate governance practices on firm performance. Professor Schoar has served as an expert witness in cases involving commercial litigation and financial services. She is co-chair of the Corporate Finance Program at the National Bureau of Economic Research and co-founder and scientific director of ideas42, a research lab on behavioral social science. She has published numerous articles and papers and received several awards for her research, including the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship, and the Brattle Group Prize in Corporate Finance for her paper “The Effects of Corporate Diversification on Productivity.” She is the executive editor of The Journal of Finance and previously served as an associate editor of the American Economic Journal: Applied Economics, the Journal of Economic Perspectives, and the Journal of Financial Intermediation. Professor Schoar’s work has been featured in The Economist, the Financial Times, The New York Times, and The Wall Street Journal.

Mr. Deal leads the economic analyses in the Menlo Park, California office and helps coordinate the firm’s Insurance practice. He combines an economics and risk analysis background with many years of experience in economic, litigation, and management consulting. He serves as a testifying and consulting expert on a wide variety of matters, often involving economic and statistical analysis of large datasets. His work as an expert has covered a variety of practice areas, including antitrust, economic damages, class action matters, and business valuation. Mr. Deal’s experience includes work in health care, insurance, finance, technology, and many other industries. He has coauthored a number of book chapters and studies, including The Economic Effects of Federal Participation in Terrorism Risk with R. Glenn Hubbard, an Analysis Group academic affiliate, former chair of the President’s Council of Economic Advisers, and former dean of the Columbia Business School.

Professor Howell’s research focuses on entrepreneurship, private equity, fintech, and innovation. She is a research associate at the National Bureau of Economic Research, a fellow at the Asian Bureau of Finance and Economic Research, and a research fellow at the Institute for Private Capital’s Private Equity Research Consortium. She has testified before the US House Committee on Ways and Means and presented her work before the US Department of Energy, Senate Committee on Small Business and Entrepreneurship, Air Force, and Centers for Medicare & Medicaid Services. Professor Howell is the recipient of the AQR Asset Management Institute Young Researcher Award and the Kauffman Foundation Junior Faculty Research Fellowship, among other awards. She also serves as an associate editor of The Review of Financial Studies and a member of the advisory board to the American Female Finance Committee of the American Finance Association. Earlier in her career, Professor Howell was an energy security policy analyst and an energy consultant.

Mr. Case is an institutional investment expert with significant expertise in the areas of investment governance, asset allocation, portfolio design and implementation, and portfolio analysis and reporting. As a former institutional investment consultant, he worked with a wide range of global clients, including insurers, health care organizations, corporate and public plan sponsors, family offices, and other large asset pools. Mr. Case was a partner at Mercer Investment Consulting, a practice leader at Evaluation Associates, and a senior consultant at Rogerscasey. He led client service teams for large clients, including defined-benefit and defined-contribution plans, insurers and mutual fund families, and registered investment advisors and foundations. As an expert, Mr. Case has evaluated various process-related issues, including the process used to monitor an ERISA plan’s investment advisor and delegated fiduciary. He previously worked as an investment analyst for AT&T’s pension investment team, oversaw the sub-advisory and pension assets of AXA Equitable Life, and managed the strategic relationship team at Putnam Investments. He is a CFA charterholder.

Dr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.

Dr. Koehn specializes in applied microeconomics and finance. He has performed research and given economic testimony in antitrust, regulatory, tax, and other business litigation matters. The author of several publications on topics such as banking and finance, energy economics, and real estate, Dr. Koehn is a former adjunct associate professor of finance at the University of California, Irvine Graduate School of Management.

Ms. Kindler is an economist with extensive experience in a variety of engagements, including intellectual property (IP) disputes, contract disputes, litigation matters related to securities and finance, false advertising allegations, and antitrust matters. She has testified numerous times in deposition, trial, and arbitration and assisted in all phases of the litigation process, including discovery, expert reports, deposition, and trial preparation. With respect to IP disputes, Ms. Kindler has evaluated damages in the context of allegations of patent infringement, trade secret misappropriation, trade dress infringement, and copyright infringement. In patent infringement matters, she has analyzed claimed lost sales, claimed lost profits, and reasonable royalty damages. Ms. Kindler also has evaluated disgorgement and actual harm in the context of numerous IP disputes. Ms. Kindler has been involved in numerous licensing negotiations related to a wide range of technologies and products, including but not limited to standard essential technology, software, smartphone and wireless technologies, dental implants, and oil and gas. In antitrust matters, she has assessed the competitive consequences of mergers, analyzed the competitive behavior of market participants, and estimated the impact of market power. Her work has also included the development of complex damages models, the analysis of statistical data, and the analysis of stock price movements. Prior to joining Analysis Group, Ms. Kindler held positions with two economics consulting firms.

Professor Savoldelli is a finance and investment expert with over 25 years of experience analyzing and advising on a wide range of hedge fund-focused issues, including fund performance, portfolio construction, fund administration, due diligence, capital raising, and asset allocation. He served as a chief investment officer for four different institutions: Optima Fund Management, Merrill Lynch, Swiss Bank Corp. Asset Management, and Chase Manhattan Private Bank. In these roles, he oversaw over $80 billion in assets.

Over the course of his investment career, Professor Savoldelli’s responsibilities included selecting hedge funds for the allocation of investor assets, making asset allocation decisions, managing investment portfolios, developing investment policies, and overseeing investment manager adherence to investment strategy and policy. He has deep experience related to the challenging issues hedge fund managers may face, including those related to fiduciary duty, disclosure, liquidation, side-pockets accounts, and valuation of complex and illiquid assets. Additionally, he is knowledgeable about the roles and responsibilities of hedge fund service providers such as prime brokers, marketers, administrators, and auditors.

At Columbia Business School, Professor Savoldelli teaches a course in the M.B.A. program on the investment strategies employed by hedge funds and best practices for the operational aspects of hedge fund management, including fund administration selection, operational risk evaluation, and leverage risk. In addition, he is a contributing editor on Bloomberg Television, commenting on developments from a hedge fund perspective.

Professor Snyder is an industrial organization economist whose research focuses on antitrust policy and enforcement, contracting practices, financial institutions, and law and economics. He has consulted on and served as a testifying expert in numerous high-profile cases, opining on liability, damages, proposed mergers, price-fixing allegations, Hatch-Waxman claims involving pharmaceuticals, monopolization claims, and proposed class certifications of both direct and indirect purchasers. In addition, Professor Snyder has testified before combined US Federal Trade Commission (FTC) and US Department of Justice (DOJ) hearings on competition and intellectual property, and has presented separately before the DOJ’s Antitrust Division, where he worked as an economist earlier in his career, and the FTC. He has been a signatory to amicus briefs submitted to the Supreme Court on various price-fixing and Sherman Act issues.

Professor Snyder has written extensively on topics related to antitrust and policy issues, with his articles appearing in prestigious publications such as The Journal of Law and Economics, the Journal of Comparative Economics, The Antitrust Bulletin, and Contemporary Policy Issues. His work has also been featured in major media outlets, including the Financial Times, The Wall Street Journal, and The New York Times.

Professor Snyder also served as the dean of the Yale School of Management from 2011 to 2019, during which time he enhanced the school’s academic programs and financial standing, and established new master’s programs in the areas of management, entrepreneurship, and executive education. He also founded the Global Network for Advanced Management at Yale University, an international consortium of schools devoted to teaching tomorrow’s business leaders around the world. Prior to joining Yale, Professor Snyder was the dean of the business schools of The University of Chicago, the University of Virginia, and the University of Michigan.

Mr. Decter specializes in the application of microeconomics, finance, and data analysis to complex securities and antitrust litigation and business strategy cases, most notably in matters related to residential mortgage-backed securities, collateralized debt obligations and credit default swaps, residential mortgage lending, mortgage reinsurance, commercial insurance, private equity, and payment cards. He has conducted damages analyses, and supported multiple experts in the areas of statistical sampling, loan and securities underwriting, damages, and loss causation.

Mr. Decter's business litigation experience focuses on finance matters in which he has managed large case teams and data sets in working with testifying experts. He supported academic affiliates in their examination of class certification issues related to commonality, predominance, and causation in In re Countrywide Financial Corp. Mortgage Marketing and Sales Practices Litigation, a mortgage marketing matter in which the plaintiff's motion for class certification was denied. Mr. Decter also supported an expert in filing a report on behalf of the defendants in New Jersey Carpenters Vacation Fund et al. v. The Royal Bank of Scotland Group plc et al., a case that marked the first major ruling on class certification among the numerous mortgage-backed securities actions pending in courts across the country at the time. He has also conducted damages analyses and worked with experts in numerous securities, antitrust, and intellectual property cases. Mr. Decter's business strategy engagements related to strategic pricing, portfolio management, and economic cost studies have spanned multiple industries, including pharmaceuticals, telecommunications, information technology, and manufacturing.

Prior to joining Analysis Group, Mr. Decter was a management consultant in the telecommunications industry. He also has several years of telecommunications industry experience in strategic planning, business development, and product management. 

Professor Jiang is a finance expert whose research focuses on corporate governance, institutional investment, technology, and financial markets. She has published extensively on M&A, as well as corporate finance and governance issues related to control changes. Her work has been published in numerous peer-reviewed journals and featured in major media outlets, including The Wall Street Journal, The Economist, Institutional Investor, Money, Fortune, Businessweek, The New York Times, and the Financial Times. Professor Jiang is the recipient of several awards for research excellence, including from The Journal of Finance, The Review of Financial Studies, and the Journal of Financial Economics, as well as best paper prizes from the Western Finance Association, the Chicago Quantitative Alliance, INQUIRE UK, the Q Group, and the Investor Responsibility Research Center Institute. She has served in editorial roles for several prominent journals, including The Review of Financial Studies, The Journal of Finance, and Management Science.

Professor Jiang is currently the vice president of the American Finance Association. Her three-year term will include a year as president-elect in 2025 and a year as president in 2026. She is also a senior fellow at the Program on Corporate Governance at Harvard Law School, a fellow at the Financial Management Association, a research associate in the Law and Economics and Corporate Finance Programs at the National Bureau of Economic Research, a member of the Committee on Capital Markets Regulation, and the president of the Society for Financial Studies. Prior to joining Goizueta Business School, Professor Jiang was the Arthur F. Burns Professor of Free and Competitive Enterprise and the vice dean for curriculum and instruction at Columbia Business School.

Professor Chalmers is an expert in securities issues, including the trading behavior of investors and the pricing of securities. He has undertaken extensive research in municipal bonds, mutual funds, and trading costs, much of which has been published in leading peer-reviewed academic journals, including The Journal of Finance, the Journal of Financial Economics, and The Review of Financial Studies. In the area of mutual funds, his research with Professors Roger Edelen and Greg Kadlec discovered and explained the source of perverse incentives exploited by so-called market timers in their trading of mutual funds. He has also written about stale pricing problems in equity mutual funds and mutual fund transaction costs, and has collaborated with other mutual fund experts, such as Professors Daniel Bergstresser and Peter Tufano, on research analyzing fund performance across fund marketing channels. He also has extensive expertise in municipal bond pricing and valuation issues. Professor Chalmers' research has been cited in reports by the General Accounting Office and in several testimonies provided before the House Financial Services Committee, as well as being widely referenced in major media outlets. He has authored several expert reports and provided testimony before the US District Court of Wisconsin.

Dr. Schatzki has a broad range of expertise in energy, environment, finance, and competition matters. He supports clients in a range of contexts, including strategic and financial advice, policy analysis, regulatory and rulemaking proceedings, and litigation.

Dr. Schatzki has deep experience in electricity, natural gas, petroleum, and renewable energy. His expertise in the electricity sector includes wholesale energy and capacity market design; utility regulation and ratemaking; economic impact analysis of new market rules, regulations, and generation and transmission investments; contract analysis and disputes; financial valuation; and options analysis. Dr. Schatzki has testified before US state and federal, as well as Canadian provincial, regulatory commissions. He has supported the analysis of alleged market manipulation and damages in high-profile litigations such as FERC v. Barclays and lawsuits following the California electricity crisis.

Dr. Schatzki works extensively on environmental economics, policy, and regulation. Recently, he has focused on the intersection of climate policy and energy markets, and disputes involving water resources and environmental contamination. His research has been published in distinguished energy- and environment-related publications, and he has provided research for prominent organizations such as the Electric Power Research Institute, the Edison Electric Institute, and the Federal Energy Regulatory Commission.

In finance and competition matters, Dr. Schatzki has worked with clients on litigation and non-litigation projects in many sectors, including energy, financial instruments, foreign exchange, insurance, airlines, and retail products. 

Professor Kothari is an expert on financial reporting and capital markets. His research interests include the measurement of security price performance, the effect of disclosures by management on the equity cost of capital, and the economic determinants of the relationship between earnings changes and stock returns. Professor Kothari also has expertise in valuation, asset allocation, and international accounting practices. From 2019 to 2021, he served as the chief economist and director of the Division of Economic and Risk Analysis at the US Securities and Exchange Commission (SEC). Professor Kothari has provided expert reports and trial testimony, and has consulted to leading US and international banks and asset management companies, US steel companies, Ernst & Young, KPMG, PricewaterhouseCoopers, and the US Department of Justice. He has published articles in peer-reviewed journals such as Management Science, The Accounting Review, and the Journal of Accounting Research. For over 20 years, Professor Kothari served as an editor of the Journal of Accounting and Economics. Previously, he was the global head of equity research for Barclays Global Investors, where he was responsible for research supporting its active equity strategies.

Ms. Kirk Fair has extensive experience leading the development of economic and market analyses, assessing class certification and damages, evaluating consumer behavior, and testifying in a wide range of matters in the US, Canada, and Europe. She has been deeply involved in merger investigations and major antitrust litigation, as well as intellectual property (IP), false advertising, and tax matters. She also is a founder of the Analysis Group’s Surveys & Experimental Studies practice.

Ms. Kirk Fair specializes in evaluating competition and substitution patterns to examine potential competitive effects in mergers and “but-for” outcomes in antitrust litigation. She has significant analytical and testifying experience in cartel matters, notably in a number of prominent cases in the technology, consumer products, and financial services industries. She also has evaluated competition, pricing, and outputs in connection with merger investigations in the US, Canada, and the EU. In addition to having served as a compliance monitor for several years, she has supported the US Department of Justice (DOJ), the Federal Trade Commission (FTC), and the Canadian Competition Bureau (CCB) in a variety of merger investigations.

Ms. Kirk Fair also has particular expertise in the development, administration, and analysis of consumer surveys for use in antitrust, false advertising, and IP matters, as well as merger reviews and strategy cases. She has testified in arbitration, deposition, and trial in matters involving the design and implementation of consumer surveys, as well as the evaluation of opposing parties’ surveys and of statistical sampling and analyses. Her work has been used to support and critique damages models and to provide insights into the role of consumer choice in market definition.

Ms. Kirk Fair serves as a Vice-Chair to the American Bar Association (ABA) Antitrust Law Section’s Pricing Conduct Committee. She has received numerous awards for her accomplishments, including the W@ “40 in Their 40s: Notable Women Competition Professionals” and the Concurrences Antitrust Writing Award for her coauthored article “The Tyranny of Market Shares: Incorporating Survey-Based Evidence into Merger Analysis” (Corporate Disputes).

Read Rebecca's profile

Professor Scharfstein is a biostatistician with expertise in the design, monitoring, and analysis of randomized clinical trials and observational studies. His research focuses on methods of reporting the results of clinical studies in which missing or censored data, non-compliance, or non-random treatment assignment may have resulted in selection bias. He has testified at deposition and trial in a number of litigation matters involving drug and medical device safety and efficacy in and outside the US. In addition, Professor Scharfstein regularly consults to the pharmaceutical industry, advising on statistical issues related to the regulatory approval of drugs and medical devices. He has served on multiple data safety monitoring boards for clinical trials, including for the National Institute of Allergy and Infectious Diseases. Professor Scharfstein is the principal biostatistician for the Major Extremity Trauma Research Consortium, which conducts multicenter clinical research studies relevant to the treatment and outcomes of orthopedic trauma sustained in the military. Professor Scharfstein is a fellow of the American Statistical Association, a recipient of the ASA’s George W. Snedecor Award for best paper in biometry, and a recipient of the Harvard T.H. Chan School of Public Health Department of Biostatistics’ Lagakos Distinguished Alumni Award. He has received multiple teaching excellence awards for his classes on probability and statistical theory.

Mr. Egland has worked on a wide range of assignments related to litigation, internal corporate consulting, and government investigations for over 35 years. He specializes in financial economics, statistical sampling, and the economics of competition. Mr. Egland directs the firm’s risk management practice, which provides comprehensive risk audits of investment portfolios. He has presented Analysis Group’s work to government regulatory agencies, to corporate boards, and in court. He has led several teams evaluating claims of excessive fees in the mutual fund industry and on ERISA cases involving the reasonableness of fees charged to 401(k) plan participants. In addition, Mr. Egland has worked on several studies assessing the risk profiles of investment portfolios. In Florida State Board of Administration v. Alliance Capital Management, he led a case team that supported six external experts in a landmark trial victory, in which a Florida jury found Alliance Capital not liable for the losses incurred by the Florida Retirement System pension fund as a result of Alliance Capital’s investments in Enron stock. He also led a case team on behalf of American Century Investments in one of the largest mutual fund excessive fee actions ever filed, which was voluntarily dismissed by the plaintiffs before trial. Mr. Egland is a CFA charterholder.

Professor Kahn’s research interests include brand management and loyalty, consumer choice and decision making, price promotions, and retailing. She has served as an expert witness and testified at deposition in numerous matters. Professor Kahn is the author of Global Brand Power: Leveraging Branding for Long-Term Growth and The Shopping Revolution: How Retailers Succeed in an Era of Endless Disruption Accelerated by COVID-19, and coauthor of Grocery Revolution: The New Focus on the Customer. She has published more than 70 articles in leading academic journals. She is a former area editor of Marketing Science, the Journal of Consumer Research, the Journal of Consumer Psychology, and the Journal of Marketing, and has served on the editorial boards of the Journal of Marketing, the Journal of Marketing Research, Marketing Science, the Journal of Consumer Research, the Journal of Behavioral Decision Making, and Marketing Letters. Prior to joining The Wharton School, Professor Kahn was on the faculty of the UCLA Anderson School of Management. She also served as dean of the Miami Herbert Business School.

Dr. Chan is a practicing internal medicine physician and an economist. His research draws on industrial organization, labor economics, and applied econometric principles to study how technology and information are used in health care, and how they affect productivity and patient care. Dr. Chan’s government service includes roles as entrepreneur in residence in the White House Office of Science and Technology Policy, staff fellow in the Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research, and medical device fellow in the FDA’s Center for Devices and Radiological Health. He has published on health economics and policy in medical and economics journals such as The New England Journal of Medicine, the Journal of Political Economy, Econometrica, and The Quarterly Journal of Economics. Dr. Chan presents frequently at national and international conferences and has received numerous grants and awards, including the National Institutes of Health Director’s High-Risk, High-Reward Early Independence Award, and a Marshall Scholarship. He is a senior fellow at the Stanford Institute for Economic Policy Research and a faculty research fellow at the National Bureau of Economic Research. 

Dr. Signorovitch advises life sciences companies on data analytics for business critical research and decision making. He has broad experience leading the strategic development and implementation of analytics across the product life cycle, from early-phase clinical studies to market access and real-world evidence generation. Dr. Signorovitch’s practice areas span trial design, multi-stakeholder collaborations, natural history studies, regulatory interactions, health economic modeling, global reimbursement submissions, policy evaluation, real-world evidence development, individualized medicine, predictive analytics, and due diligence for acquisitions. He has particular expertise in developing and applying new methodologies to address health care research challenges, and in designing analytics platforms to enhance collaborative research and decision making. Dr. Signorovitch’s work has been used to inform clinical regulators and health care payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology.

Professor Syverson is an expert in industrial organization and microeconomics. His research spans numerous topics related to the interactions of firm structure, market structure, and productivity. Professor Syverson has been retained as an expert in several engagements and has provided deposition testimony in antitrust litigation. He has published widely in leading economic and industry journals, including the Journal of Economic Perspectives, the American Economic Review, and Econometrica, and he coauthored the intermediate-level textbook Microeconomics. Professor Syverson’s research has received multiple grants from the National Science Foundation, among others. He is a former editor of the Journal of Political Economy and has served on a number of editorial boards. Professor Syverson is a research associate in several programs at the National Bureau of Economic Research, including Productivity, Innovation, and Entrepreneurship; Industrial Organization; and Environment and Energy Economics. Prior to his appointment at The University of Chicago, he was a mechanical engineer for Loral Defense Systems and Unisys. He holds undergraduate degrees in both mechanical engineering and economics from the University of North Dakota.

Dr. Lehmann specializes in applying microeconomics, econometrics, and statistical methods to complex litigation and government investigations in the areas of antitrust and competition, labor and employment, health care, and commercial damages. She has evaluated market definition, market power, competitive dynamics, class certification, liability, and damages issues in cases involving allegations of price-fixing, monopolization, and other anticompetitive conduct. Dr. Lehmann has extensive experience in labor market antitrust matters involving allegations of no-poach and wage-fixing agreements in a variety of industries. In her work with pharmaceutical and medical device industries, she has analyzed economic, health, and scientific data to assess liability, damages, and claims of causation and harm. She also frequently supports biostatisticians, epidemiologists, scientists, and regulatory experts in evaluating research and development processes and analyzing clinical trial, laboratory testing, registry, medical claims, and adverse events data in product liability litigations and intellectual property disputes. She has authored expert reports and provided testimony on class certification, damages, causation assessments, and statistical issues in antitrust and competition, data security breach, labor and employment, and commercial litigation matters.

Dr. Lehmann’s research has been published in the Journal of Economic Literature, The Journal of Human Resources, Labour Economics, Cartel & Joint Conduct Review, Distribution, Cybersecurity Law & Strategy, Antitrust Report, and Antitrust Magazine, and her academic work has been cited in leading media outlets, including Scientific American, Forbes, and BBC News. She serves as a co-chair of the Distribution and Franchising Committee of the American Bar Association (ABA) Antitrust Law Section. Prior to joining Analysis Group, Dr. Lehmann was an assistant professor of economics at the University of Houston, where she taught courses in labor economics and microeconomics.

Dr. Kupiec’s research interests include quantitative financial risk measurement, systemic risk, deposit insurance, and the regulation of banking and financial services. At the American Enterprise Institute, he has authored several studies on systemic risk measurement and related regulations, bank stress testing, and bank regulations that follow financial crisis, including their impact on the wider economy. Dr. Kupiec was an associate director of the Division of Insurance and Research and director of the Center for Financial Research (CFR) at the Federal Deposit Insurance Corporation. In these roles, he oversaw research on bank risk measurement that contributed to the development and implementation of regulatory policies, including the international Basel III framework. He also served as chairman of the Research Task Force of the Basel Committee on Banking Supervision. Dr. Kupiec has worked at the International Monetary Fund, Freddie Mac, and J.P. Morgan, as well as for the Division of Research and Statistics at the Board of Governors of the Federal Reserve System. Prior to entering the financial services industry, Dr. Kupiec was an assistant professor of finance at North Carolina State University. He has published articles in several academic journals, including The Journal of Finance, the Journal of Financial Intermediation, the Journal of Financial Stability, the Journal of Financial Services Research, The Journal of Risk, and the Journal of Investment Management.